These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29308196)

  • 1. Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash.
    Usui N; Kondo Y; Ryota N; Suzuki H; Okamoto N; Sando M; Tani E; Hamaguchi M; Tanaka A; Tamiya M; Shiroyama T; Morishita N; Tanaka E; Hirashima T
    Eur J Hosp Pharm; 2017 Sep; 24(5):283-285. PubMed ID: 29308196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effectiveness of steroids for the rash side effect of pemetrexed].
    Ishikawa H; Onishi T; Kobayashi R; Ohashi Y; Suzuki K; Yamamoto N; Shino M
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):75-8. PubMed ID: 23306922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone alleviates pemetrexed-induced senescence in Non-Small-Cell Lung Cancer.
    Ge H; Ke J; Xu N; Li H; Gong J; Li X; Song Y; Zhu H; Bai C
    Food Chem Toxicol; 2018 Sep; 119():86-97. PubMed ID: 29753869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
    Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
    Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids.
    Sakurada T; Kakiuchi S; Tajima S; Horinouchi Y; Konaka K; Okada N; Nishisako H; Nakamura T; Teraoka K; Kawazoe K; Yanagawa H; Nishioka Y; Ishizawa K
    Biol Pharm Bull; 2015; 38(11):1752-6. PubMed ID: 26521826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
    Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
    Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
    Ding L; Liu K; Jiang Z; Chen Q; Zhou N; Liang Y; Gao H; Hong X; Wu H
    Tumour Biol; 2015 Apr; 36(4):2491-9. PubMed ID: 25417899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.
    Sumiyoshi I; Okabe T; Togo S; Takagi H; Motomura H; Ochi Y; Shimada N; Haraguchi M; Shibayama R; Fujimoto Y; Watanabe J; Iwai M; Kadoya K; Iwakami SI; Takahashi K
    J Transl Med; 2021 Feb; 19(1):92. PubMed ID: 33639962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.
    Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study.
    Jun N; Hanping W; Xiaoyan S; Yan X; Mengzhao W; Xiaotong Z; Li Z
    Thorac Cancer; 2020 Jul; 11(7):1869-1875. PubMed ID: 32406994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.
    Miyahara T; Sueoka-Aragane N; Iwanaga K; Ureshino N; Komiya K; Nakamura T; Nakashima C; Abe T; Matsunaga H; Kimura S
    Med Oncol; 2017 Nov; 34(12):195. PubMed ID: 29124473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
    Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
    J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
    Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
    Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy.
    Nakashima K; Murakami H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Endo M; Takahashi T
    Mol Clin Oncol; 2016 Nov; 5(5):575-578. PubMed ID: 27900087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancer.
    Yoon JY; Park CK; Choi YD; Oh IJ; Kim YC
    Thorac Cancer; 2019 Apr; 10(4):942-949. PubMed ID: 30864258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
    Niho S; Yoshida T; Akimoto T; Sakamaki K; Ono A; Seto T; Nishio M; Yamamoto N; Hida T; Okamoto H; Kurata T; Satouchi M; Goto K; Yamanaka T; Ohe Y
    Lung Cancer; 2020 Mar; 141():64-71. PubMed ID: 31955002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of cutaneous reactions with pemetrexed: Comparison of patients who received three days of oral dexamethasone twice daily to patients who did not.
    Clark SK; Anselmo LM
    J Oncol Pharm Pract; 2019 Oct; 25(7):1645-1650. PubMed ID: 30319062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
    Wehler T; Thomas M; Schumann C; Bosch-Barrera J; Viñolas Segarra N; Dickgreber NJ; Dalhoff K; Sebastian M; Corral Jaime J; Alonso M; Hynes SM; Lin J; Hurt K; Bence Lin A; Calvo E; Paz-Ares L
    Lung Cancer; 2017 Jun; 108():212-216. PubMed ID: 28625637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Wielage R; Muehlenbein C; Liepa AM; Babineaux S; Lawson A; Schwartzberg L
    J Thorac Oncol; 2010 Aug; 5(8):1263-72. PubMed ID: 20581708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.